Skip to main content
Top
Published in: BMC Oral Health 1/2023

Open Access 01-12-2023 | Human Immunodeficiency Virus | Study Protocol

Oral health outcomes in an HIV cohort with comorbidities- implementation roadmap for a longitudinal prospective observational study

Authors: Temitope T. Omolehinwa, Sunday O. Akintoye, Marta Gabinskiy, Vincent Lo Re III, Mel Mupparapu, Rosa Urbina, Douglas E. Schaubel, Patricia M. Corby

Published in: BMC Oral Health | Issue 1/2023

Login to get access

Abstract

Background

Long-term antiretroviral therapy (ART) perpetually suppresses HIV load and has dramatically altered the prognosis of HIV infection, such that HIV is now regarded as a chronic disease. Side effects of ART in Patients With HIV (PWH), has introduced new challenges including “metabolic” (systemic) and oral complications. Furthermore, inflammation persists despite great viral load suppression and normal levels of CD4+ cell count.
The impact of ART on the spectrum of oral diseases among PWH is often overlooked relative to other systemic complications. There is paucity of data on oral complications associated with ART use in PWH. This is in part due to limited prospective longitudinal studies designed to better understand the range of oral abnormalities observed in PWH on ART.

Methods

We describe here the study design, including processes associated with subject recruitment and retention, study visit planning, oral health assessments, bio-specimen collection and preprocessing procedures, and data management and statistical plan.

Discussion

We present a procedural roadmap that could be modelled to assess the extent and progression of oral diseases associated with ART in PWH. We also highlight the rigors and challenges associated with our ongoing participant recruitment and retention.
A rigorous prospective longitudinal study requires proper planning and execution. A great benefit is that large data sets are collected and biospecimen repository can be used to answer more questions in future studies including genetic, microbiome and metabolome-based studies.

Trial registration

National Institute of Health Clinical Trials Registration (NCT) #: NCT04645693.
Literature
1.
go back to reference Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10(5):e332–42.CrossRefPubMed Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10(5):e332–42.CrossRefPubMed
3.
go back to reference Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Current HIV/AIDS Rep. 2013;10(1):21–32.CrossRef Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Current HIV/AIDS Rep. 2013;10(1):21–32.CrossRef
5.
go back to reference Alberti KG, Zimmet P, Shaw J, Group I. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–62.CrossRefPubMed Alberti KG, Zimmet P, Shaw J, Group I. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–62.CrossRefPubMed
6.
go back to reference Ahmed D, Roy D, Cassol E. Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy. Mediators Inflamm. 2018;6238978:eCollection. Ahmed D, Roy D, Cassol E. Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy. Mediators Inflamm. 2018;6238978:eCollection.
7.
go back to reference Echecopar-Sabogal J, D’Angelo-Piaggio L, Chanamé-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis. Int J STD AIDS. 2018;29:443–52.CrossRefPubMed Echecopar-Sabogal J, D’Angelo-Piaggio L, Chanamé-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis. Int J STD AIDS. 2018;29:443–52.CrossRefPubMed
8.
go back to reference Willig AL, Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016;13(5):289–96.CrossRefPubMedPubMedCentral Willig AL, Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016;13(5):289–96.CrossRefPubMedPubMedCentral
9.
go back to reference Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep. 2011;13(1):51–6.CrossRefPubMed Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep. 2011;13(1):51–6.CrossRefPubMed
10.
go back to reference Pandiyan P, Younes SA, Ribeiro SP, Talla A, McDonald D, Bhaskaran N, et al. Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation. Front Immunol. 2016;20(7):228. Pandiyan P, Younes SA, Ribeiro SP, Talla A, McDonald D, Bhaskaran N, et al. Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation. Front Immunol. 2016;20(7):228.
11.
go back to reference Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, et al. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses. 2019;11(3):200.CrossRefPubMedPubMedCentral Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, et al. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses. 2019;11(3):200.CrossRefPubMedPubMedCentral
12.
go back to reference Maggi P, Di Biagio A, Rusconi S, Cicalini S, D’Abbraccio M, d’Ettorre G, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis DIseases. 2017;17(1):551.CrossRef Maggi P, Di Biagio A, Rusconi S, Cicalini S, D’Abbraccio M, d’Ettorre G, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis DIseases. 2017;17(1):551.CrossRef
13.
go back to reference Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, et al. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother. 2012;56(8):4154–60.CrossRefPubMedPubMedCentral Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, et al. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother. 2012;56(8):4154–60.CrossRefPubMedPubMedCentral
14.
go back to reference Toljić B, Trbovich AM, Petrović SM, Kannosh IY, Dragović G, Jevtović D, et al. Ageing with HIV - a periodontal perspective. New Microbiol. 2018;41(1):61–6.PubMed Toljić B, Trbovich AM, Petrović SM, Kannosh IY, Dragović G, Jevtović D, et al. Ageing with HIV - a periodontal perspective. New Microbiol. 2018;41(1):61–6.PubMed
15.
go back to reference Pólvora TLS, Nobre ÁVV, Tirapelli C, Taba M, Macedo LDd, Santana RC, et al. Relationship between human immunodeficiency virus (HIV-1) infection and chronic periodontitis. London. Expert Rev Clin Immunol. 2018;14(4):315–27.CrossRefPubMed Pólvora TLS, Nobre ÁVV, Tirapelli C, Taba M, Macedo LDd, Santana RC, et al. Relationship between human immunodeficiency virus (HIV-1) infection and chronic periodontitis. London. Expert Rev Clin Immunol. 2018;14(4):315–27.CrossRefPubMed
16.
go back to reference Lomelí-Martínez SM, González-Hernández LA, Ruiz-Anaya AJ, Lomelí-Martínez MA, Martínez-Salazar SY, Mercado González AE, et al. Oral Manifestations Associated with HIV/AIDS Patients. Medicina (Kaunas). 2022;58(9):1214.CrossRefPubMedPubMedCentral Lomelí-Martínez SM, González-Hernández LA, Ruiz-Anaya AJ, Lomelí-Martínez MA, Martínez-Salazar SY, Mercado González AE, et al. Oral Manifestations Associated with HIV/AIDS Patients. Medicina (Kaunas). 2022;58(9):1214.CrossRefPubMedPubMedCentral
17.
go back to reference French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200(8):1212–5.CrossRefPubMed French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200(8):1212–5.CrossRefPubMed
18.
go back to reference Pedersen AML, Sørensen CE, Proctor GB, Carpenter GH, Ekström J. Salivary secretion in health and disease. J Oral Rehabil. 2018;45(9):730–46.CrossRefPubMed Pedersen AML, Sørensen CE, Proctor GB, Carpenter GH, Ekström J. Salivary secretion in health and disease. J Oral Rehabil. 2018;45(9):730–46.CrossRefPubMed
19.
go back to reference Nizamuddin I, Koulen P, McArthur CP. Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands. Int J Mol Sci. 2018;19(9):E2747.CrossRef Nizamuddin I, Koulen P, McArthur CP. Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands. Int J Mol Sci. 2018;19(9):E2747.CrossRef
20.
go back to reference Shiboski CH, Yao TJ, Russell JS, Ryder MI, Van Dyke RB, Seage GR, et al. The association between oral disease and type of antiretroviral therapy among perinatally HIV-infected youth. AIDS. 2018;32(17):2497–505.CrossRefPubMed Shiboski CH, Yao TJ, Russell JS, Ryder MI, Van Dyke RB, Seage GR, et al. The association between oral disease and type of antiretroviral therapy among perinatally HIV-infected youth. AIDS. 2018;32(17):2497–505.CrossRefPubMed
21.
go back to reference Hodgson TA, Greenspan D, Greenspan JS. Oral lesions of HIV disease and HAART in industrialized countries. Adv dent res. 2006;19(1):57–62.CrossRefPubMed Hodgson TA, Greenspan D, Greenspan JS. Oral lesions of HIV disease and HAART in industrialized countries. Adv dent res. 2006;19(1):57–62.CrossRefPubMed
22.
go back to reference Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):523–9.CrossRefPubMedPubMedCentral Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):523–9.CrossRefPubMedPubMedCentral
23.
go back to reference Pinheiro A, Marcenes W, Zakrzewska JM, Robinson PG. Dental and oral lesions in HIV infected patients. Int Dent J. 2004;54(3):131–7.CrossRefPubMed Pinheiro A, Marcenes W, Zakrzewska JM, Robinson PG. Dental and oral lesions in HIV infected patients. Int Dent J. 2004;54(3):131–7.CrossRefPubMed
24.
go back to reference Ceballos-Salobreña A, Gaitán-Cepeda LA, Ceballos-Garcia L, Lezama-Del VD. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDs. 2000;14(12):627–35.CrossRefPubMed Ceballos-Salobreña A, Gaitán-Cepeda LA, Ceballos-Garcia L, Lezama-Del VD. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDs. 2000;14(12):627–35.CrossRefPubMed
25.
go back to reference Kelesidis T, Currier JS, Yang OO, Brown TT. Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. AIDS Review. 2014;16(3):123–33. Kelesidis T, Currier JS, Yang OO, Brown TT. Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. AIDS Review. 2014;16(3):123–33.
26.
go back to reference Biver E, Calmy A, Rizzoli R. Bone health in HIV and hepatitis B or C infections. TAMD. 2017;9(1):22–34. Biver E, Calmy A, Rizzoli R. Bone health in HIV and hepatitis B or C infections. TAMD. 2017;9(1):22–34.
27.
go back to reference Dalla GE, Rigo F, Lanzafame M, Lattuada E, Suardi S, Mottes M, et al. Relationship Between Vertebral Fractures, Bone Mineral Density, and Osteometabolic Profile in HIV and Hepatitis B and C-Infected Patients Treated With ART. Front Endocrinol (Lausanne). 2019;10:302.CrossRef Dalla GE, Rigo F, Lanzafame M, Lattuada E, Suardi S, Mottes M, et al. Relationship Between Vertebral Fractures, Bone Mineral Density, and Osteometabolic Profile in HIV and Hepatitis B and C-Infected Patients Treated With ART. Front Endocrinol (Lausanne). 2019;10:302.CrossRef
28.
go back to reference Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23.CrossRefPubMed Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23.CrossRefPubMed
29.
go back to reference Han X, Kawai T, Eastcott JW, Taubman MA. Bacterial-responsive B lymphocytes induce periodontal bone resorption. J Immunol. 2006;176(1):625–31.CrossRefPubMed Han X, Kawai T, Eastcott JW, Taubman MA. Bacterial-responsive B lymphocytes induce periodontal bone resorption. J Immunol. 2006;176(1):625–31.CrossRefPubMed
30.
go back to reference Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27(15):2425–30.CrossRefPubMed Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27(15):2425–30.CrossRefPubMed
31.
go back to reference Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74.CrossRefPubMed Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74.CrossRefPubMed
32.
go back to reference Subith S, Tungenwar S, Avhad T, Apte T, Dakhode S. Anti-retroviral Therapy-Induced Multiple Pathological Fractures in a HIV-Positive Young Female: A Case Report and Review of Literature. J Orthop Case Rep. 2023;13(5):111–5.CrossRefPubMedPubMedCentral Subith S, Tungenwar S, Avhad T, Apte T, Dakhode S. Anti-retroviral Therapy-Induced Multiple Pathological Fractures in a HIV-Positive Young Female: A Case Report and Review of Literature. J Orthop Case Rep. 2023;13(5):111–5.CrossRefPubMedPubMedCentral
33.
go back to reference Lastrucci L, Bertocci S, Bini V, Borghesi S, De Majo R, Rampini A, et al. Xerostomia Quality of Life Scale (XeQoLS) questionnaire: validation of Italian version in head and neck cancer patients. Radiol Med (Torino). 2018;123(1):44–7.CrossRefPubMed Lastrucci L, Bertocci S, Bini V, Borghesi S, De Majo R, Rampini A, et al. Xerostomia Quality of Life Scale (XeQoLS) questionnaire: validation of Italian version in head and neck cancer patients. Radiol Med (Torino). 2018;123(1):44–7.CrossRefPubMed
34.
go back to reference Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral oncol. 2001;37(1):84–93.CrossRefPubMed Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral oncol. 2001;37(1):84–93.CrossRefPubMed
36.
go back to reference Bagley AF, Ye R, Garden AS, Gunn GB, Rosenthal DI, Fuller CD, et al. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020;142:133–9.CrossRefPubMed Bagley AF, Ye R, Garden AS, Gunn GB, Rosenthal DI, Fuller CD, et al. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020;142:133–9.CrossRefPubMed
38.
go back to reference Thornhill MH, Dayer M, Prendergast BD, Lockhart P, Baddour L. Antibiotic Prophylaxis in Dentistry. Clin Infect Dis. 2023;76(5):960–1.CrossRefPubMed Thornhill MH, Dayer M, Prendergast BD, Lockhart P, Baddour L. Antibiotic Prophylaxis in Dentistry. Clin Infect Dis. 2023;76(5):960–1.CrossRefPubMed
39.
go back to reference Binkley N, Kiebzak GM, Lewiecki EM, Krueger D, Gangnon RE, Miller PD, et al. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. JBMR. 2005;20(2):195–201.CrossRef Binkley N, Kiebzak GM, Lewiecki EM, Krueger D, Gangnon RE, Miller PD, et al. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. JBMR. 2005;20(2):195–201.CrossRef
Metadata
Title
Oral health outcomes in an HIV cohort with comorbidities- implementation roadmap for a longitudinal prospective observational study
Authors
Temitope T. Omolehinwa
Sunday O. Akintoye
Marta Gabinskiy
Vincent Lo Re III
Mel Mupparapu
Rosa Urbina
Douglas E. Schaubel
Patricia M. Corby
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Oral Health / Issue 1/2023
Electronic ISSN: 1472-6831
DOI
https://doi.org/10.1186/s12903-023-03527-5

Other articles of this Issue 1/2023

BMC Oral Health 1/2023 Go to the issue